Global Payments Inc vs Illumina, Inc. — how do they compare? Global Payments Inc trades at $80.27 (market cap $21.40B), while Illumina, Inc. trades at $189.49 (market cap $28.32B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Global Payments Inc pays a 1.28% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| GPN | ILMN | |
|---|---|---|
Market Cap | $21.40B | $28.32B |
Sector | Industrials | Health |
52-Week High | $90.01 | $194.33 |
52-Week Low | $62.47 | $91.00 |
Enterprise Value | $39.11B | $29.70B |
Dividend Yield | 1.28% | — |
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $79.67, up 4.98% today, with a bullish technical outlook and strong earnings beats in recent quarters. The company shows robust operating cash flow of $2.66B in 2025 and benefits from strategic initiatives like the Worldpay integration and AI-powered POS expansions. However, net income margin turned negative at -7.97% for 2026, reflecting margin pressures amid rising costs and competitive fintech landscape.
GPN presents a mixed outlook: analyst consensus is bullish with a $81.56 price target (58% buy ratings), but investors face risks from debt growth (debt-to-asset ratio rising to 41.57% in 2025) and profitability challenges. Near-term catalysts include continued execution on commerce technology deals, while volatility may persist from macroeconomic headwinds.
Illumina (ILMN) trades at $188.27, down 1.53% on the day, yet maintains a strong technical and fundamental posture. The stock is in a bullish trend, supported by consistent earnings beats, robust profitability margins, and positive analyst sentiment. Recent news highlights strong momentum in 2026, driven by sequencing demand and new product launches, positioning the company for growth despite competitive pressures.
The outlook for ILMN is positive, with earnings growth and market leadership in genomics offering upside potential. Key risks include intensifying competition from new entrants like Roche and execution challenges in a dynamic healthcare landscape. Investor sentiment remains buoyant, but vigilance on competitive threats and margin sustainability is warranted for sustained performance.
Trailing returns across standard periods
Latest headlines on both assets
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →